These three biotech stocks should turn out to be outstanding long-term growth vehicles.
News & Analysis: Gilead Sciences
Two rising biotech stocks. One clear long-term winner.
These two biotechs could have a tortoise-and-hare kind of race going on.
Its been a tough few years for investors in this big-cap biotech, but signals are emerging that better days are ahead.
Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.
Gilead's new CEO, Dan O'Day, gives several hints about where the big biotech is headed in his comments in the Q1 earnings conference call.
Gilead's first-quarter numbers beat expectations. Is it time to buy?
The biotech delivered solid growth in the first quarter on both the top and bottom lines, thanks to strong sales for HIV drug Biktarvy and some good news for its HCV franchise.
GILD earnings call for the period ending March 31, 2019.
Which of these top biotech stocks is the more attractive long-term buy?